Bahl & Gaynor Inc. reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,574 shares of the medical equipment provider’s stock after selling 28 shares during the quarter. Bahl & Gaynor Inc.’s holdings in Zimmer Biomet Holdings were worth $1,298,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. MARSHALL WACE ASIA Ltd acquired a new stake in Zimmer Biomet Holdings during the 1st quarter valued at $38,621,000. Cibc World Markets Corp raised its stake in Zimmer Biomet Holdings by 52.9% during the 1st quarter. Cibc World Markets Corp now owns 21,007 shares of the medical equipment provider’s stock valued at $2,565,000 after purchasing an additional 7,269 shares during the period. Caxton Associates LP acquired a new stake in Zimmer Biomet Holdings during the 1st quarter valued at $403,000. Jensen Investment Management Inc. raised its stake in Zimmer Biomet Holdings by 24.2% during the 2nd quarter. Jensen Investment Management Inc. now owns 5,850 shares of the medical equipment provider’s stock valued at $751,000 after purchasing an additional 1,140 shares during the period. Finally, Commerce Bank raised its stake in Zimmer Biomet Holdings by 1.5% during the 2nd quarter. Commerce Bank now owns 218,171 shares of the medical equipment provider’s stock valued at $28,013,000 after purchasing an additional 3,142 shares during the period. 85.48% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/09/17/zimmer-biomet-holdings-inc-zbh-holdings-cut-by-bahl-gaynor-inc.html.

Shares of Zimmer Biomet Holdings, Inc. (NYSE ZBH) opened at 115.47 on Friday. The firm’s 50-day moving average is $114.88 and its 200-day moving average is $120.74. The company has a market capitalization of $23.35 billion, a PE ratio of 32.89 and a beta of 1.21. Zimmer Biomet Holdings, Inc. has a 12-month low of $95.63 and a 12-month high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.10 by ($0.02). Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The business had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. During the same quarter in the previous year, the firm posted $2.02 earnings per share. The firm’s quarterly revenue was up 1.1% on a year-over-year basis. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 annualized dividend and a dividend yield of 0.83%. Zimmer Biomet Holdings’s dividend payout ratio is presently 27.59%.

A number of equities analysts have recently weighed in on ZBH shares. Royal Bank Of Canada upped their price target on shares of Zimmer Biomet Holdings from $133.00 to $140.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 21st. Bank of America Corporation reaffirmed a “buy” rating and issued a $158.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. BidaskClub downgraded shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $135.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 28th. Finally, Zacks Investment Research downgraded shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and an average price target of $136.75.

In other news, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $121.74, for a total transaction of $2,067,875.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 1.07% of the stock is owned by insiders.

Zimmer Biomet Holdings Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.